Hepatology News, Info, Symptoms

* Hepatology101 SEARCH *

*Filter: "Cirrhosis"

Cirrhosis - Symptoms and causes - Mayo Clinic
How is it treated? Although the damage caused by cirrhosis is not reversible, treatment can slow the progression of the disease, alleviate symptoms, and prevent complications. In cases of early cirrhosis, it is possible to minimize damage to the liver by tackling the underlying causes.

Cirrhosis of the Liver: What It Is, Symptom & Treatment
Cirrhosis of the liver is a late stage of chronic liver disease. At this stage, a significant amount of your healthy liver tissue has turned to scar tissue. Scarring comes from long-term inflammation in your liver (hepatitis). When you have too much scar tissue, it can prevent your liver from working properly. This leads to liver failure. While cirrhosis can’t be reversed, treatment may slow ...

Cirrhosis - Wikipedia
Cirrhosis, also known as liver cirrhosis, hepatic cirrhosis, chronic liver failure, chronic hepatic failure, and end-stage liver disease, is a chronic condition of the liver in which the normal functioning tissue, or parenchyma, is replaced with scar tissue (fibrosis) and regenerative nodules as a result of chronic liver disease. [6][7][8 ...

Cirrhosis of the Liver: Symptoms, Stages, and Treatment - WebMD
Cirrhosis is a condition in which scar tissue gradually replaces your healthy liver cells. It usually happens over a long period, often due to hepatitis, alcohol use disorder, or metabolic ...

Cirrhosis of the Liver: Symptoms, Causes & Treatments
Cirrhosis is caused by chronic (long-term) liver diseases that damage liver tissue. It can take many years for liver damage to lead to cirrhosis.

Cirrhosis of the liver life expectancy: Stages, outlook, and more
Cirrhosis of the liver is a serious condition, which causes permanent liver damage. Life expectancy depends greatly on the stage and type. Learn more here.

Cirrhosis - Diagnosis and treatment - Mayo Clinic
Once cirrhosis becomes decompensated, average life expectancy drops to about two years without liver transplant. Many things can influence life expectancy for each person, including complications and treatment.

Cirrhosis - NIDDK
Overview of cirrhosis, a condition in which your liver is scarred and permanently damaged. Describes causes, symptoms, complications, diagnosis, and treatment.

Cirrhosis: Causes, Symptoms, Treatment - Healthline
Cirrhosis is the severe scarring and limited function of the liver caused by long-term exposure to toxins such as alcohol or viral infections.

Cirrhosis - NHS
Find out about cirrhosis, including what the symptoms are, who's more likely to have it and treatments.

* Hepatology101 LATEST NEWS *

                    *Filter: "Cirrhosis"

Cirrhosis, portal hypertension and hepatocellular carcinoma: a stage-based approach  Nature
From EASL 2026: What Hepatology Still Needs to Solve  The American Journal of Managed Care
UCHealth opens new outreach clinic for liver disease in Boulder  UCHealth
Cedars-Sinai Research Identifies Drivers of Liver Disease  Cedars-Sinai
Metabolic Surgery May Reverse MASH Cirrhosis, Paired Biopsy Study Suggests  Cleveland Clinic
The role of primary care in response to the global liver disease syndemic: a Lancet Gastroenterology & Hepatology Commission  The Lancet
Terlipressin May Improve Decompensated Cirrhosis  Gastroenterology & Endoscopy News
GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease  UC San Diego Health
Role of spot urine analyses in patients with cirrhosis and ascites as the single first decompensation event  elsevier.es
Surveillance Report #123  National Institute on Alcohol Abuse and Alcoholism (NIAAA) (.gov)
A New Therapy for People Suffering from Abdominal Fluid Buildup Caused by Liver Cirrhosis  dartmouth-hitchcock.org
Study Explores How Coffee May Protect the Liver  Cedars-Sinai
Accurately identifying cirrhosis and its complications to create the novel statewide Indiana digital cirrhosis registry  Nature
Recompensation in decompensated cirrhosis  The Lancet
Impact of adding statins to non-selective beta-blockers in cirrhosis with portal hypertension: a systematic review and meta-analysis of randomized controlled trials  elsevier.es

Common Hepatology Symptoms

Jaundice (Icterus) — Yellowing of the skin and sclera caused by elevated serum bilirubin levels due to impaired hepatic processing or biliary obstruction.

Ascites — Pathologic accumulation of fluid in the peritoneal cavity, commonly secondary to portal hypertension and advanced liver cirrhosis.

Hepatic Encephalopathy — Spectrum of neuropsychiatric abnormalities including confusion, asterixis, and altered consciousness resulting from neurotoxin accumulation.

Pruritus — Severe, generalized skin itching frequently associated with cholestatic liver diseases and systemic bile acid accumulation.

Right Upper Quadrant Abdominal Pain — Dull ache or sensation of fullness caused by stretching of Glisson's capsule surrounding an enlarged or inflamed liver.

Spider Angiomas and Palmar ErytHepa — Vascular cutaneous signs stemming from altered sex hormone metabolism and hyperdynamic circulation in chronic liver disease.

Dark Urine and Acholic Stools — Tea-colored urine from bilirubinuria paired with pale, clay-colored stools indicating impaired biliary drainage.

Milestones in Hepatology History

Discovery of the Australia Antigen (1965) — Baruch Blumberg identified the surface antigen of Hepatitis B, paving the way for diagnostic screening and the first HBV vaccine.

First Successful Human Liver Transplant (1967) — Dr. Thomas Starzl performed the world's first successful human liver transplantation at the University of Colorado Health Sciences Center.

Identification of Hepatitis Delta Virus (1977) — Mario Rizzetto discovered the delta antigen, characterizing HDV as a defective subviral pathogen reliant on HBV co-infection.

Cloning and Identification of Hepatitis C (1989) — Michael Houghton, Harvey Alter, and Charles Rice isolated the non-A, non-B hepatitis virus, officially naming it Hepatitis C.

Introduction of MELD Score System (2002) — The Model for End-Stage Liver Disease was adopted in the United States to prioritize liver allocation based on 3-month mortality risk.

Approval of Direct-Acting Antivirals for HCV (2013) — The FDA approved Sofosbuvir, ushering in an era of highly effective, interferon-free oral curative regimens for chronic Hepatitis C.

Nomenclature Shift to MASLD and MASH (2023) — Global liver societies renamed NAFLD/NASH to better reflect underlying metabolic pathology and eliminate stigmatizing language.

Current Hepatology Research

Bepirovirsen Functional Cure Trials — Evaluating antisense oligonucleotides to achieve a sustained loss of HBsAg and drug-free clinical response in patients living with chronic hepatitis B.

MASLD Diagnostics and Screening — Refining non-invasive biomarker panels and metabolic criteria to detect metabolic dysfunction-associated steatotic liver disease early in co-infected populations.

Hepatitis D Expanded Testing Protocols — Implementing reflexive antibody and RNA testing strategies to address global underdiagnosis of delta hepatitis co-infections.

Global Elimination Strategy Implementation — Tracking regional epidemiological data and public health interventions designed to accelerate viral hepatitis eradication goals.

RNA Interference (RNAi) Gene Silencing — Investigating small interfering RNA therapies to knock down viral transcripts and reduce antigen production in chronic liver infections.

MASH Fibrosis Biomarker Development — Validating novel serum panels and elastography metrics to monitor metabolic dysfunction-associated steatohepatitis regression without invasive biopsies.

In Vivo Gene Editing via Lipid Nanoparticles — Utilizing hepatic-targeted LNP delivery systems to correct monogenic metabolic liver disorders directly within host hepatocytes.

Gut Microbiome Alterations in Cirrhosis — Analyzing gut-liver axis dysbiosis to prevent bacterial translocation and manage portal hypertension complications in end-stage liver disease.